文献速递肿瘤 PET/CT核素与放射性配体治疗

RECIP 1.0 在生化复发前列腺癌[68Ga]Ga-PSMA-11 PET图像中手动与人工智能分割的预后价值

Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-08-08

本研究在199例生化复发前列腺癌患者中验证RECIP 1.0标准,患者于生化复发时及中位6.0个月后行[68Ga]Ga-PSMA-11 PET/CT,期间接受标准治疗。结论认为RECIP 1.0在该人群中具有预后价值,且对两种分割方法稳健。

要点

  • RECIP 1.0在半自动分割下可区分生化复发前列腺癌患者的生存差异。
  • AI分割获得的RECIP分类同样与总生存相关,两种方法一致性为fair(Cohen's k=0.31)。
  • RECIP 1.0可用于评估疾病进展程度较低的前列腺癌患者。

核心结论

  • RECIP 1.0在生化复发前列腺癌人群中显示出预后价值,且对两种不同分割方法(包括新型AI方法)稳健。
  • RECIP 1.0可用于评估疾病进展程度较低的前列腺癌患者的疾病进展。

研究设计与样本

  • 199例生化复发前列腺癌患者于生化复发时行[68Ga]Ga-PSMA-11 PET/CT,中位6.0个月后再次显像以评估疾病进展,期间接受标准治疗。
  • 全身肿瘤体积在半自动分割下于全部患者中量化(TTVman),并在亚组(n=74)中使用新型AI方法量化(TTVAI),其余患者用于模型训练。
  • 采用Kaplan-Meier法、log rank检验及单因素Cox回归分析RECIP分类与总生存的关联,采用Cohen's kappa统计量评估手动与AI反应分类的一致性。
  • 本研究于2015年6月11日在澳大利亚新西兰临床试验注册中心注册(ACTRN12615000608561)。

主要发现

  • 半自动与AI-based RECIP分类总体一致性为fair(Cohen's k=0.31)。

关键数值与推荐

  • RECIP-PD定义为按RECIP 1.0标准判定的进展性疾病,非RECIP-PD为非进展性疾病。
  • 半自动分割下RECIP-PD组26/199例(13.1%),AI分割下RECIP-PD组12/74例(16.2%)。

临床怎么用

  • 原文结论认为RECIP 1.0可用于评估疾病进展程度较低的前列腺癌患者的疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to (i) validate the Response Evaluation Criteria in PSMA (RECIP 1.0) criteria in a cohort of biochemically recurrent (BCR) prostate cancer (PCa) patients and (ii) determine if this classification could be performed fully automatically using a trained artificial intelligence (AI) model. METHODS: One hundred ninety-nine patients were imaged with [68Ga]Ga-PSMA-11 PET/CT once at the time of biochemical recurrence and then a second time a median of 6.0 months later to assess disease progression. Standard-of-care treatments were administered to patients in the interim. Whole-body tumour volume was quantified semi-automatically (TTVman) in all patients and using a novel AI method (TTVAI) in a subset (n = 74, the remainder were used in the training process of the model). Patients were classified as having progressive disease (RECIP-PD), or non-progressive disease (non RECIP-PD). Association of RECIP classifications with patient overall survival (OS) was assessed using the Kaplan-Meier method with the log rank test and univariate Cox regression analysis with derivation of hazard ratios (HRs). Concordance of manual and AI response classifications was evaluated using the Cohen's kappa statistic. RESULTS: Twenty-six patients (26/199 = 13.1%) presented with RECIP-PD according to semi-automated delineations, which was associated with a significantly lower survival probability (log rank p < 0.005) and higher risk of death (HR = 3.78 (1.96-7.28), p < 0.005). Twelve patients (12/74 = 16.2%) presented with RECIP-PD according to AI-based segmentations, which was also associated with a significantly lower survival (log rank p = 0.013) and higher risk of death (HR = 3.75 (1.23-11.47), p = 0.02). Overall, semi-automated and AI-based RECIP classifications were in fair agreement (Cohen's k = 0.31). CONCLUSION: RECIP 1.0 was demonstrated to be prognostic in a BCR PCa population and is robust to two different segmentation methods, including a novel AI-based method. RECIP 1.0 can be used to assess disease progression in PCa patients with less advanced disease. This study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12615000608561) on 11 June 2015.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kendrick J, Francis RJ, Hassan GM, et al. Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images. Eur J Nucl Med Mol Imaging. 2023. PMID: 37550494. doi:10.1007/s00259-023-06382-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。